ANI Pharmaceuticals ANIP Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 60.8%+1.5pp | 61.4%+2.1pp | 61.1%+1.4pp | 61.1%-0.3pp | 59.3%-3.4pp | |
| Net margin | 10%+13.1pp | 8.9%+11.9pp | 4.9%+6.2pp | -1.4%-6.4pp | -3.1%-10.0pp | |
| EBITDA margin | 23.1%+13.1pp | 22.9%+14.3pp | 17.9%+4.9pp | 11.3%-9.1pp | 9.9%-12.7pp | |
| Free cash flow margin | 20.7%+10.8pp | 19.4%+11.6pp | 18.8%+5.0pp | 16.8%-1.7pp | 9.9%-10.4pp | |
| Returns | ||||||
| Return on equity | 18.8%+23.6pp | 16.6%+21.0pp | 8.9%+10.6pp | -2.3%-8.5pp | -4.8%-14.1pp | |
| Return on assets | 6.8%+8.7pp | 5.7%+7.4pp | 3%+3.7pp | -0.9%-3.9pp | -1.9%-6.1pp | |
| Return on invested capital | 17.2%+18.9pp | 15.7%+18.4pp | 7.9%+5.8pp | -0%-9.7pp | -1.6%-12.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.7×+0.1× | 0.6×0.0× | |
| Inventory turnover | 2.6×+0.4× | 2.4×+0.4× | 2.2×+0.4× | 2.2×+0.4× | 2.2×+0.4× | |
| Liquidity | ||||||
| Current ratio | 3.1×+0.5× | 2.7×0.0× | 2.6×-0.2× | 2.5×-1.4× | 2.7×-1.3× | |
| Quick ratio | 2.5×+0.5× | 2.2×+0.2× | 2×+0.1× | 2×-1.1× | 2×-1.1× | |
| Cash ratio | 1.3×+0.6× | 1×+0.3× | 1×+0.2× | 0.9×-0.8× | 0.7×-0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×-0.2× | 0.6×-0.2× | 0.6×-0.2× | 0.7×+0.1× | 0.8×+0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×-0.1× | 0.2×-0.1× | |
| Net debt / EBITDA | -0×-2.5× | 0.2×-3.2× | 0.4×-2.1× | 1.1×+0.7× | 2.5×+2.0× | |
| Per Share | ||||||
| Book value per share | $26.10+25.0% | $25.47+21.9% | $23.98+14.6% | $21.51-8.8% | $20.88-10.3% | |
| Valuation | ||||||
| Market capitalization | $1.72B+18.3% | $1.77B+52.6% | $2.04B+62.7% | $1.45B+8.6% | $1.46B0.0% | |
| Enterprise value | $1.72B+5.8% | $1.81B+34.7% | $2.1B+46.7% | $1.55B+12.1% | $1.62B+7.3% | |
| Price / sales | 1.9×-0.3× | 2×+0.1× | 2.5×+0.2× | 1.9×-0.5× | 2.2×-0.7× | |
| Price / book | 3.1×-0.4× | 3.3×+0.4× | 4×+0.9× | 3.3×+0.4× | 3.5×+0.3× | |
| EV / EBITDA | 8.1×-16.2× | 8.9×-16.4× | 14.2×-5.7× | 18.3×+5.8× | 24.2×+11.3× | |
| EV / sales | 1.9×-0.5× | 2×-0.1× | 2.5×0.0× | 2.1×-0.5× | 2.4×-0.5× | |
| Free cash flow yield | 11.1%+6.5pp | 9.7%+5.6pp | 7.6%+1.5pp | 8.7%+1.2pp | 4.6%-2.6pp | |
| Earnings yield | 5.3%+6.8pp | 4.4%+6.0pp | 2%+2.6pp | -0.7%-2.7pp | -1.4%-3.9pp | |
| Dividend yield | 0%-0.1pp | 0.1%-0.1pp | 0.1%-0.1pp | 0.1%0.0pp | 0.1%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ANI Pharmaceuticals's profit margins?
- ANI Pharmaceuticals (ANIP) runs a 60.8% gross margin and a 13.4% operating margin, with a 10.0% net margin.
- Where do ANI Pharmaceuticals's ratios come from?
- Every ratio is computed from ANI Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.